#154807

Anti-BrdU [BU20a] rAb

Cat. #154807

Anti-BrdU [BU20a] rAb

Cat. #: 154807

Sub-type: Primary antibody

Unit size: 100 ug

Availability: 10-12 weeks

Target: Bromodeoxyuridine (BrdU)

Class: Recombinant

Application: IHC

Reactivity: Human

Host: Mouse

£300.00

This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.

Contributor

Institute: Absolute Antibody; University of Oxford

Tool Details
Target Details
Applications
Handling
References

Tool Details

*FOR RESEARCH USE ONLY

  • Name: Anti-BrdU [BU20a] rAb
  • Clone: BU20a
  • Tool sub type: Primary antibody
  • Class: Recombinant
  • Conjugation: Unconjugated
  • Reactivity: Human
  • Host: Mouse
  • Application: IHC
  • Description: Recombinant monoclonal antibody detects proliferating cells in the S phase via binding the synthetic nucleoside BrdU. Background and Research Application Bromodeoxyuridine (5-bromo-2-deoxyuridine, BrdU) is a synthetic nucleoside that is an analogue of thymidine. BrdU is commonly used in the detection of proliferating cells in living tissues. It can be incorporated into the newly synthesized DNA of replicating cells, within the S phase of the cell cycle instead of thymidine. This is a recombinant version of the anti-BrdU monoclonal antibody . Anti-BrdU works well in immunohistochemistry to identify cells in tissue sections or cytospin preparations that have incorporated BrdU. This indicates cells that were actively replicating their DNA. Anti-BrdU stains BrdU incorporated into the nuclei of a wide range of cell types, including human tonsil lymphoid cells and human tumours growing in nude mice. It is also useful to identify cells in S phase during FACS analysis. Anti-BrdU can be used to analyse the phenotype of S-phase cells and in co-localizing antigen expression and BrdU incorporation in tissue sections. This antibody was created to replace similar use polyclonal antibodies which frequently cross reacted with other nucleotides. Binding of this antibody requires denaturation of the DNA, usually by exposing the cells to acid or heat.
  • Immunogen: Bromodeoxyuridine conjugated to BSA
  • Immunogen uniprot id: B0WM48
  • Isotype: IgG1

Target Details

  • Target: Bromodeoxyuridine (BrdU)
  • Target background: Recombinant monoclonal antibody detects proliferating cells in the S phase via binding the synthetic nucleoside BrdU. Background and Research Application Bromodeoxyuridine (5-bromo-2-deoxyuridine, BrdU) is a synthetic nucleoside that is an analogue of thymidine. BrdU is commonly used in the detection of proliferating cells in living tissues. It can be incorporated into the newly synthesized DNA of replicating cells, within the S phase of the cell cycle instead of thymidine. This is a recombinant version of the anti-BrdU monoclonal antibody. Anti-BrdU works well in immunohistochemistry to identify cells in tissue sections or cytospin preparations that have incorporated BrdU. This indicates cells that were actively replicating their DNA. Anti-BrdU stains BrdU incorporated into the nuclei of a wide range of cell types, including human tonsil lymphoid cells and human tumours growing in nude mice. It is also useful to identify cells in S phase during FACS analysis. Anti-BrdU can be used to analyse the phenotype of S-phase cells and in co-localizing antigen expression and BrdU incorporation in tissue sections. This antibody was created to replace similar use polyclonal antibodies which frequently cross reacted with other nucleotides. Binding of this antibody requires denaturation of the DNA, usually by exposing the cells to acid or heat.

Applications

  • Application: IHC

Handling

  • Format: Liquid
  • Concentration: 1 mg/ml
  • Unit size: 100 ug
  • Storage buffer: 0.1M PBS + 0.5M imidazole at pH 7.4. 0.05% ProClin300TM. This product was purified using affinity chromatography (protein A)PtXTM Anti-Î?-Tubulin Full IgG is 90 % pure in relation to other proteins in the sample.
  • Storage conditions: Store at -20° C frozen. Avoid repeated freeze / thaw cycles
  • Shipping conditions: Shipping at 4° C

References

  • 4PD Fnized Dendrimers: A Flexible Tool for In Vivo Gene Silencing of Tumor-Educated Myeloid Cells.
  • CBP/catenin antagonist safely eliminates drug-resistant leukemia-initiating cells.
  • Cui et al. 2015. Cell. 161(4):750-61. PMID: 25957683.
  • Double immunocytochemical labeling of cell and tissue samples with monoclonal anti-bromodeoxyuridine.
  • Fn assessment of glioma pathogenesis by in vivo multi-parametric magnetic resonance imaging and in vitro analyses.
  • IL-7-Induced Glycerol Transport and TAG Synthesis Promotes Memory CD8+ T Cell Longevity.
  • Innis et al. 2010. Am J Physiol Gastrointest Liver Physiol. 299(6):G1376-85. PMID: 20864654.
  • Intratracheal cell transfer demonstrates the profibrotic potential of resident fibroblasts in pulmonary fibrosis.
  • Involvement of SDF1a and STAT3 in granulocyte colony-stimulating factor rescues optic ischemia-induced retinal function loss by mobilizing hematopoietic stem cells.
  • Kim et al. 2016. Int J Dev Neurosci. :. PMID: 27326907.
  • Lin et al. 2013. Invest Ophthalmol Vis Sci. 54(3):1920-30. PMID: 23439595.
  • Magaud et al. 1989. J Histochem Cytochem. 37(10):1517-27. PMID: 2476478.
  • Maternal obesity leads to increased proliferation and numbers of astrocytes in the developing fetal and neonatal mouse hypothalamus.
  • MOZ (MYST3, KAT6A) inhibits senescence via the INK4A-ARF pathway.
  • N-Myc and the cyclin-dependent kinase inhibitors p18Ink4c and p27Kip1 coordinately regulate cerebellar development.
  • Perinatal lipid nutrition alters early intestinal development and programs the response to experimental colitis in young adult rats.
  • Sheikh et al. 2015. Oncogene. PMID: 25772242.
  • Tsukui et al. 2015. Am J Pathol. :. PMID: 26456579.
  • Yao et al. 2016. Sci Rep. 6:26050. PMID: 27198662.
  • Zhao et al. 2015. Oncogene. :. PMID: 26657156.
  • Zilio et al. 2017. J Immunol. :. PMID: 28396317.
  • Zindy et al. 2006. Proc Natl Acad Sci U S A. 103(31):11579-83. PMID: 16864777.
  • Desamero et al. 2019. Sci Rep. 9(1):19635. PMID: 31873082.
  • Helbling-Leclerc et al. 2019. Sci Rep. 9(1):17024. PMID: 31745226.
  • Paul et al. 2019. J Immunother Cancer. 7(1):208. PMID: 31387637.
  • Dick et al. 2019. Nat Immunol. 20(5):664. PMID: 30862954.
  • Xu et al. 2019. Sci Adv. 5(4):eaav4570. PMID: 31032410.
  • Jimenez et al. 2019. Front Immunol. 10:2183. PMID: 31620123.